Neurotransmitters Involved in Bipolar Disorder
Bipolar disorder involves dysregulation of multiple neurotransmitter systems, with the most prominent being monoamines (dopamine, norepinephrine, serotonin), glutamate, and GABA, operating through disrupted limbic-thalamo-cortical circuitry 1.
Primary Neurotransmitter Systems
Monoaminergic Systems
The monoaminergic neurotransmitters represent the cornerstone of bipolar disorder pathophysiology 1:
Dopamine: Alterations in the dopaminergic system occur through catechol-O-methyltransferase (COMT) variants and changes in dopamine receptor expression 2. The dopaminergic system plays a critical role in reward processing and cognitive/affective processes that are disrupted in bipolar disorder.
Norepinephrine and Serotonin: A specific imbalance exists in the locus coeruleus, where depressed bipolar patients show significantly reduced tyrosine hydroxylase immunoreactivity (26.7% vs 50.7% in controls) and tryptophan hydroxylase immunoreactivity (11.7% vs 32.8% in controls) 3. This represents a unique finding in bipolar disorder that distinguishes it from unipolar depression, where these changes are not observed.
Serotonin transporter: Genetic variants and altered receptor binding in monoaminergic genes, particularly the serotonin transporter and monoamine oxidase A, show association with bipolar disorder 4.
Glutamatergic System
Glutamate represents a major excitatory neurotransmitter system with substantial evidence of dysfunction in bipolar disorder 5:
- Glutamatergic neurons originating in the prefrontal cortex project to the striatum and are central to cortico-striato-thalamo-cortical (CSTC) circuitry
- Chemical neuroimaging studies demonstrate altered glutamate neurotransmission and cellular metabolism, particularly pronounced within the hippocampus 5
- Genetic studies implicate glutamatergic system genes including SLC1A1, GRIN2B, GRID2, and DLGAP1 2
- Abnormalities of ionotropic glutamate receptors are found within the hippocampus 5
GABAergic System
While less extensively detailed in the available evidence, GABA as the primary inhibitory neurotransmitter is implicated in the neurotransmitter imbalance characteristic of bipolar disorder 1.
Signal Transduction Pathways
Beyond direct neurotransmitter alterations, bipolar disorder involves disruption of intracellular signaling cascades 6:
- Second messenger systems: Cyclic AMP (cAMP), protein kinase A, phosphoinositide pathways, glycogen synthase kinase-3, protein kinase B, and Wnt signaling
- Calcium signaling dysregulation: Including genome-wide findings for voltage-dependent calcium channel α-1 subunit 2
- Transcription factors: Alterations in cAMP response element binding protein (CREB), β-catenin, and other transcription factors that connect neurotransmitter receptor activation to gene expression 6
Clinical Implications
The multi-neurotransmitter dysfunction explains why mood stabilizers targeting different systems are necessary for treatment 7. Lithium, valproate, and lamotrigine work through distinct mechanisms affecting these various neurotransmitter pathways, while atypical antipsychotics primarily target dopaminergic and serotonergic systems 8, 7.
The pattern of neurotransmitter abnormalities suggests that bipolar disorder involves greater neural inefficiency and altered reactivity to emotional stimuli rather than fixed structural lesions 5. This functional dysregulation across multiple neurotransmitter systems underlies the varied clinical symptoms—from manic episodes with excessive dopaminergic activity to depressive episodes with monoaminergic deficits.
A critical clinical caveat: The neurotransmitter imbalance in bipolar disorder differs fundamentally from unipolar depression, particularly in the locus coeruleus findings 3. This distinction supports why antidepressants should never be used as monotherapy in bipolar disorder, as they may destabilize mood or precipitate manic episodes by further disrupting the already dysregulated neurotransmitter balance 8.